

EVOLUT™ TAVI  
**HEALTH CANADA  
LICENCED  
FOR LOW RISK**

AND ALSO

**FIRST AND ONLY  
TAVI PLATFORM**

HEALTH CANADA  
APPROVED FOR  
TREATMENT OF  
PATIENTS WITH

**SEVERE BICUSPID  
AORTIC STENOSIS\***

\* Evolut™ TAVI Platform is indicated for treatment of patients with severe Bicuspid Aortic Stenosis who are at intermediate or greater risk for SAVR.

**Medtronic**


Further, Together



## WHY EVOLUT™ IN BICUSPID PATIENTS? DESIGNED FOR EXCELLENT PATIENT OUTCOMES

The Evolut™ platform offers patients with **BICUSPID** aortic valve disease excellent hemodynamics.<sup>3</sup>

MEAN AORTIC VALVE GRADIENT<sup>2</sup>




Number of Echos:

<b>Bicuspid</b>	<b>187</b>	<b>116</b>
Tricuspid	6426	4267

The supra annular design of the Evolut™ TAVI platform allows for exceptional hemodynamics in challenging, bicuspid anatomies.<sup>4</sup>

## EVOLUT™ TAVI COMPARED TO SAVR

TAVI showed lower mortality, fewer disabling strokes, and fewer heart failure rehospitalizations compared to SAVR.<sup>1</sup>



- HF Hospitalization
- Disabling Stroke
- Death

Difference = +4.5%

P = 0.002

**TAVI** 5.6%  
**SAVR** 10.2%  
Composite Rates

## SUPERIOR HEMODYNAMICS IN LOW RISK PATIENTS<sup>2</sup>

Evolut™ TAVI is currently **THE ONLY** TAVI device to demonstrate hemodynamics superiority in a low risk clinical trial vs. SAVR at one year.<sup>2</sup>

SUPERIOR  
EOAs

**Evolut™ TAVI**  
**2.3 cm<sup>2</sup>**  
VS.  
**SAVR 2.0 cm<sup>2</sup>**

SUPERIOR  
Gradients

**Evolut™ TAVI**  
**8.6 mm Hg**  
VS.  
**SAVR**  
**11.2 mm Hg**

15%

**LARGER EOAs**

23%

**LOWER GRADIENTS**

# HEMODYNAMICS MATTER

Patients benefit from larger EOAs, which decreases the risk of Patient Prosthesis Mismatch (PPM) and improves exercise capacity, helping them return to an active life.<sup>5,6</sup>



PPM  
CALCULATOR  
TOOL  
PPMMATTERS.COM

## Less Patient Prosthesis Mismatch, Better Patient Outcomes.<sup>7\*\*</sup>

\*\* Severe PPM is associated with increased mortality and HF rehospitalizations at 1 year.

1. Reardon MJ. The Evolut Low Risk Trial. Presented at ACC 2019; New Orleans, LA.
2. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. *N Engl J Med.* May 2, 2019;380(18):1706-1715.
3. John K. Forrest et al Self-Expanding Transcatheter Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Bicuspid Valve Morphology A Report from the Society of Thoracic Surgeons / American College of Cardiology Transcatheter Valve Therapy Registry™ CR T19.
4. Philip F, Faza NN, Schoenhagen P, et al. Aortic annulus and root characteristics in severe aortic stenosis due to bicuspid aortic valve and tricuspid aortic valves: implications for transcatheter aortic.
5. Bleiziffer S, Eichinger WB, Hettich I, et al. Impact of patient-prosthesis mismatch on exercise capacity in patients after bioprosthetic aortic valve replacement. *Heart.* May 2008;94(5):637-641.
6. Van Slooten YJ, van Melle JP, Freling HG, et al. Aortic valve prosthesis-patient mismatch and exercise capacity in adult patients with congenital heart disease. *Heart.* January 2016;102(2):107-113.
7. Herrmann HC, Daneshvar SA, Fonarow GC, et al. Prosthesis-Patient Mismatch in 62,125 Patients Following Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry. *J Am Coll Cardiol.* Published online September 18, 2018.

## Medtronic

Medtronic Canada  
99 Hereford Street  
Brampton, Ontario L6Y 0R3  
Canada  
Tel: (905) 460-3800  
Toll-free: (800) 268-5346

[medtronic.ca](http://medtronic.ca)

Please reference the CoreValve™ Evolut™ R and CoreValve™ Evolut™ PRO instruction for use for more information regarding indications, warnings, precautions, and potential adverse events. The commercial name of the Evolut™ R device is Medtronic CoreValve™ Evolut™ R System, and the commercial name of the Evolut™ PRO device is Medtronic Corevalve™ Evolut™ PRO System. See the CoreValve™ Evolut™ R and CoreValve™ Evolut™ PRO device manuals for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at [medtronic.eu](http://medtronic.eu). For applicable products, consult instructions for use on [manuals.medtronic.com](http://manuals.medtronic.com). Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.

UC202010013 EC © 2020 Medtronic.  
All Rights Reserved.

